Clinical Trial Update: Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection

View source ↗

Summary

A completed clinical trial evaluated whether AHCC, a Lentinula edodes-derived supplement, can promote clearance of persistent human papillomavirus infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• AHCC (Active Hexose Correlated Compound)

Snippet

Sponsor: Liaquat University of Medical & Health Sciences | Conditions: HPV Infection | Status: COMPLETED